BioNTech SE (BNTX) Net Income Quarterly: History & Chart

BioNTech SE(BNTX)

Biotechnology · Mainz, RP

$99.21-4.55 (-4.38%)

Delayed quote: Sep 8, 2026, 11:00 AM EDT

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Mainz, RP

7,807 employees

www.biontech.com/de/de/home.html

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ugur Sahin

View full financials

Quarterly Net Income

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly quarterly net income is ($937.50M). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.

Net Income TTM|Net Income CAGR|Profit Margin|Financials

Quarterly Net Income

BNTX Quarterly Net Income

$-937.50M

Reported quarterly net income; no daily interpolation.

≈65x over 10Y

BNTX P/E Ratio

Full P/E Ratio page

P/E Ratio

BNTX P/E Ratio Chart

165.66

+3853.70% 1Y

BNTX Earnings Yield

Full Earnings Yield page

Earnings Yield

BNTX Earnings Yield Chart

0.60%

-97.49% 1Y

Quarterly Net Income History

Period	Quarterly Net Income	% Change
Quarter ended Jun 2026	($937.50M)	N/A
Quarter ended Mar 2026	($624.62M)	N/A
Quarter ended Dec 2025	($354.89M)	N/A
Quarter ended Sep 2025	($33.68M)	N/A
Quarter ended Jun 2025	($455.68M)	N/A
Quarter ended Mar 2025	($449.68M)	(267.35%)
Quarter ended Dec 2024	$268.71M	+21.82%
Quarter ended Sep 2024	$220.57M	N/A
Quarter ended Jun 2024	($865.22M)	N/A
Quarter ended Mar 2024	($339.97M)	(167.27%)
Quarter ended Dec 2023	$505.41M	+197.62%
Quarter ended Sep 2023	$169.82M	N/A
Quarter ended Jun 2023	($207.72M)	(138.15%)
Quarter ended Mar 2023	$544.51M	(77.67%)
Quarter ended Dec 2022	$2.44B	+39.37%
Quarter ended Sep 2022	$1.75B	(0.20%)
Quarter ended Jun 2022	$1.75B	(57.18%)
Quarter ended Mar 2022	$4.09B	+13.57%
Quarter ended Dec 2021	$3.60B	(3.03%)
Quarter ended Sep 2021	$3.72B	+12.48%
Quarter ended Jun 2021	$3.30B	+149.73%
Quarter ended Mar 2021	$1.32B	+195.23%
Quarter ended Dec 2020	$448.21M	N/A
Quarter ended Sep 2020	($246.10M)	N/A
Quarter ended Jun 2020	($99.19M)	N/A
Quarter ended Mar 2020	($58.90M)	N/A
Quarter ended Dec 2019	($65.34M)	N/A
Quarter ended Sep 2019	($32.80M)	N/A
Quarter ended Jun 2019	($56.93M)	N/A
Quarter ended Mar 2019	($45.59M)	N/A
Quarter ended Dec 2018	($1.55M)	N/A
Quarter ended Sep 2018	($27.19M)	N/A
Quarter ended Jun 2018	($13.57M)	N/A
Quarter ended Mar 2018	($14.31M)	N/A